Disclosure notice

Disclosure notice Stockholm, August 25, 2005 Johan Löf, Erik Hedlund, Anders Brahme, Carl Filip Bergendal and Anders Liander (”the Principal Owners”) divested 400,000 B shares in RaySearch Laboratories AB (publ) (”RaySearch”) on August 25, 2005. This corresponds to 0.8 % of the votes and 3.5 % of the capital in RaySearch. Accordingly, as of August 25, 2005 the Principal Owners hold shares corresponding to 79.1% of the votes and 45.8% of the capital in RaySearch. Johan Löf sold 220,536 shares, Erik Hedlund 55,357 shares, Anders Brahme 49,107 shares, Carl Filip Bergendal 37,500 and Anders Liander 37,500 shares, all of which were series B. Refer to the table below regarding the Principal Owners’ shareholdings after the sales. A key purpose of the Principal Owners’ sales was to continue to enhance conditions for improved liquidity in the RaySearch B share, which is listed on the Attract40 segment of the O List of the Stockholm Stock Exchange. The Principal Owners will remain as long-term majority owners in RaySearch. Johan Löf, Erik Hedlund, Anders Brahme and Carl Filip Bergendal are together bound to retain a voting majority in RaySearch through 2012 in accordance with an agreement with two of the company’s main cooperation partners. The purchasers of the shares were a number of international and swedish investors. The holdings of the main shareholders after the sales are shown below. A sharesB sharesVotes in %Capital in % Johan Löf2,081,028779,46443.625.0 Erik Hedlund 522,363201,32010.96.3 Anders Brahme 463,387177,7649.75.6 Carl Filip Bergendal 353,859136,3777.44.3 Anders Liander 353,859166,5357.54.6 Total3,774,496 1,461,460 79.145.8 Handelsbanken was the financial advisor to RaySearch and the Principal Owners. For further information: Johan Löf President and CEO, RaySearch Laboratories AB Telephone: +46 (0)8-545 061 30 johan.lof@raysearchlabs.com About RaySearch RaySearch develops and sells software for radiation therapy for cancer treatment. The products are specially developed to optimize radiation therapy and the purpose is to adapt the radiation dose to the shape of the tumor, which allows high doses to be delivered to the tumor while minimizing the dose to surrounding healthy tissue. RaySearch, a spin-off from Karolinska Institute, was formed in 2000. RaySearch has sold its product RayOptimizer to more than 800 hospitals around the world through a licensing agreement with Philips, enabling more than a hundred thousand patients to receive improved radiation therapy. RaySearch was listed on the Stockholm Stock Exchange O List in November 2003. As of July 1, 2005, RaySearch is listed on the Attract40 segment of the O List of the Stockholm Stock Exchange. Sales of the products RayBiology and RayMachine began in 2004. The partnership with Philips continues and RaySearch signed a licensing agreement with Nucletron at the beginning of 2004. The latter agreement made RaySearch's products available to a large number of new clinics worldwide and, consequently, increased the number of potential end customers sharply. Delivery to clinics of OM-Optimizer, the first product based on the partnership with Nucletron, began in April 2005. RaySearch is based in Stockholm and currently has 28 employees. RaySearch Laboratories AB (publ) Sveavägen 25 SE-111 34 Stockholm Telephone: +46 8 545 061 30 Company website: www.raysearchlabs.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=124716&fn=wkr0001.pdf